Atara Biotherapeutics, Inc.
ATRA
$15.63
$1.6511.80%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -38.63% | 258.77% | 670.30% | 1,779.79% | 2,892.69% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -38.63% | 258.77% | 670.30% | 1,779.79% | 2,892.69% |
| Cost of Revenue | -88.03% | -10.37% | -24.66% | -13.41% | -92.16% |
| Gross Profit | -29.12% | 450.22% | 93.56% | 80.24% | 141.35% |
| SG&A Expenses | -33.40% | 2.61% | -9.13% | -14.91% | -33.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -72.36% | -8.02% | -21.86% | -13.66% | -35.73% |
| Operating Income | 126.41% | 283.48% | 77.10% | 68.75% | 74.97% |
| Income Before Tax | 112.55% | 219.80% | 78.97% | 68.59% | 73.21% |
| Income Tax Expenses | -- | -- | -272.73% | 10.53% | -- |
| Earnings from Continuing Operations | 112.53% | 219.71% | 79.00% | 68.61% | 73.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 112.53% | 219.71% | 79.00% | 68.61% | 73.21% |
| EBIT | 126.41% | 283.48% | 77.10% | 68.75% | 74.97% |
| EBITDA | 132.98% | 300.80% | 78.68% | 69.99% | 75.75% |
| EPS Basic | 106.31% | 162.53% | 91.52% | 82.11% | 81.67% |
| Normalized Basic EPS | 110.54% | 192.61% | 90.45% | 82.10% | 82.01% |
| EPS Diluted | 106.13% | 161.95% | 91.52% | 82.11% | 81.67% |
| Normalized Diluted EPS | 110.45% | 191.86% | 90.45% | 82.10% | 82.01% |
| Average Basic Shares Outstanding | 98.55% | 91.43% | 147.61% | 75.42% | 46.12% |
| Average Diluted Shares Outstanding | 100.39% | 92.98% | 147.61% | 75.42% | 46.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |